New triple-threat approach targets deadly mesothelioma in early trial

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab and a special imaging technique during surgery can improve treatment for malignant pleural mesothelioma, a rare and aggressive lung cancer. About 20 adults with measurable disease will receive the combination. The main goal is to check safety and side effects, with secondary goals of seeing how long the cancer stays controlled and overall survival.